4-Hydroxyandrostenedione treatment for postmenopausal patients with advanced breast cancer. 1987

R C Coombes, and P E Goss, and M Dowsett, and G Hutchinson, and D Cunningham, and M Jarman, and A M Brodie
Ludwig Institute for Cancer Research, St. George's Hospital Medical School, London, UK.

We have treated 128 postmenopausal women with advanced breast cancer with 4-hydroxyandrostenedione. Of these, 118 were assessable for toxicity and 100 for response to treatment. Response to therapy was seen in 34% of patients and stabilization of disease in 12 patients. Three dose regimens were used (500 mg intramuscularly weekly; 250 mg intramuscularly every 2 weeks; and 500 mg orally daily). There was no difference in response in these three groups. Side effects were minimal and local reaction to injected drug was seen in 13% of patients. The sole severe side effect observed was neutropenia which was transient and reversible on discontinuing therapy. 4-Hydroxyandrostenedione is an effective nontoxic agent in the treatment of breast cancer.

UI MeSH Term Description Entries
D007273 Injections, Intramuscular Forceful administration into a muscle of liquid medication, nutrient, or other fluid through a hollow needle piercing the muscle and any tissue covering it. Intramuscular Injections,Injection, Intramuscular,Intramuscular Injection
D008593 Menopause The last menstrual period. Permanent cessation of menses (MENSTRUATION) is usually defined after 6 to 12 months of AMENORRHEA in a woman over 45 years of age. In the United States, menopause generally occurs in women between 48 and 55 years of age. Change of Life, Female
D009376 Neoplasms, Hormone-Dependent Certain tumors that 1, arise in organs that are normally dependent on specific hormones and 2, are stimulated or caused to regress by manipulation of the endocrine environment. Hormone-Dependent Neoplasms,Hormone Dependent Neoplasms,Hormone-Dependent Neoplasm,Neoplasm, Hormone-Dependent,Neoplasms, Hormone Dependent
D011960 Receptors, Estrogen Cytoplasmic proteins that bind estrogens and migrate to the nucleus where they regulate DNA transcription. Evaluation of the state of estrogen receptors in breast cancer patients has become clinically important. Estrogen Receptor,Estrogen Receptors,Estrogen Nuclear Receptor,Estrogen Receptor Type I,Estrogen Receptor Type II,Estrogen Receptors Type I,Estrogen Receptors Type II,Receptor, Estrogen Nuclear,Receptors, Estrogen, Type I,Receptors, Estrogen, Type II,Nuclear Receptor, Estrogen,Receptor, Estrogen
D001943 Breast Neoplasms Tumors or cancer of the human BREAST. Breast Cancer,Breast Tumors,Cancer of Breast,Breast Carcinoma,Cancer of the Breast,Human Mammary Carcinoma,Malignant Neoplasm of Breast,Malignant Tumor of Breast,Mammary Cancer,Mammary Carcinoma, Human,Mammary Neoplasm, Human,Mammary Neoplasms, Human,Neoplasms, Breast,Tumors, Breast,Breast Carcinomas,Breast Malignant Neoplasm,Breast Malignant Neoplasms,Breast Malignant Tumor,Breast Malignant Tumors,Breast Neoplasm,Breast Tumor,Cancer, Breast,Cancer, Mammary,Cancers, Mammary,Carcinoma, Breast,Carcinoma, Human Mammary,Carcinomas, Breast,Carcinomas, Human Mammary,Human Mammary Carcinomas,Human Mammary Neoplasm,Human Mammary Neoplasms,Mammary Cancers,Mammary Carcinomas, Human,Neoplasm, Breast,Neoplasm, Human Mammary,Neoplasms, Human Mammary,Tumor, Breast
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000284 Administration, Oral The giving of drugs, chemicals, or other substances by mouth. Drug Administration, Oral,Administration, Oral Drug,Oral Administration,Oral Drug Administration,Administrations, Oral,Administrations, Oral Drug,Drug Administrations, Oral,Oral Administrations,Oral Drug Administrations
D000735 Androstenedione A delta-4 C19 steroid that is produced not only in the TESTIS, but also in the OVARY and the ADRENAL CORTEX. Depending on the tissue type, androstenedione can serve as a precursor to TESTOSTERONE as well as ESTRONE and ESTRADIOL. 4-Androstene-3,17-dione,delta-4-Androstenedione,4 Androstene 3,17 dione,delta 4 Androstenedione

Related Publications

R C Coombes, and P E Goss, and M Dowsett, and G Hutchinson, and D Cunningham, and M Jarman, and A M Brodie
September 1992, The Journal of steroid biochemistry and molecular biology,
R C Coombes, and P E Goss, and M Dowsett, and G Hutchinson, and D Cunningham, and M Jarman, and A M Brodie
January 1990, Cancer chemotherapy and pharmacology,
R C Coombes, and P E Goss, and M Dowsett, and G Hutchinson, and D Cunningham, and M Jarman, and A M Brodie
January 1992, European journal of cancer (Oxford, England : 1990),
R C Coombes, and P E Goss, and M Dowsett, and G Hutchinson, and D Cunningham, and M Jarman, and A M Brodie
May 1990, Journal of clinical oncology : official journal of the American Society of Clinical Oncology,
R C Coombes, and P E Goss, and M Dowsett, and G Hutchinson, and D Cunningham, and M Jarman, and A M Brodie
April 1993, Cancer treatment reviews,
R C Coombes, and P E Goss, and M Dowsett, and G Hutchinson, and D Cunningham, and M Jarman, and A M Brodie
August 1993, British journal of cancer,
R C Coombes, and P E Goss, and M Dowsett, and G Hutchinson, and D Cunningham, and M Jarman, and A M Brodie
January 1987, Cancer chemotherapy and pharmacology,
R C Coombes, and P E Goss, and M Dowsett, and G Hutchinson, and D Cunningham, and M Jarman, and A M Brodie
March 1989, Cancer research,
R C Coombes, and P E Goss, and M Dowsett, and G Hutchinson, and D Cunningham, and M Jarman, and A M Brodie
January 1983, European journal of cancer & clinical oncology,
R C Coombes, and P E Goss, and M Dowsett, and G Hutchinson, and D Cunningham, and M Jarman, and A M Brodie
January 1992, Breast cancer research and treatment,
Copied contents to your clipboard!